Clinical trials: Tumor Immunity
Cervical Cancer, Cervical Intraepithelial Neoplasia
The Correlations Between HPV L1-Specific Immunologic Responses in Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN) Patients and Their Prognosis
A. To investigate the relationship between serum titer of anti-HPV16 antibody and clinicopathological factors of cervical cancer patients. B.
- Trial name
- NCT00728871
- Testing
- peripheral blood isolation
- Where
- China
- Volunteers
- 600 people
- Sponsor
- National Taiwan University Hospital
Colorectal Surgery
Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer
The purpose of this study is to compare postoperative immune function (e.g. NK cell activity) of fentanyl-based analgesic regimen versus local anesthetic wound infiltration-based anlagesic regimen after laparoscopic colorectal…
- Trial name
- NCT02012244
- Testing
- fentanyl-based analgesia, local anesthetic wound infiltration-based anlagesia
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Severance Hospital
Uterine Cervical Neoplasms
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
BVAC-C is an immunotherapeutic vaccine using B-Cell and Monocytes as antigen-presenting cells. This study is consists of 2 parts. Phase I is for safety evaluation, and Phase IIa is for efficacy assessment.
- Trial name
- NCT02866006
- Testing
- BVAC-C, Topotecan
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Cellid Co., Ltd.
BRAF V600E Mutation Present, BRAF V600K Mutation Present
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase I trial studies the side effects and best way to give ipilimumab with or without dabrafenib, trametinib and/or nivolumab in treating patients with melanoma that has spread to other parts of the body…
- Conditions
- BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
- Trial name
- NCT01940809
- Testing
- Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
Our proposed study is designed to test the safety of a new vaccine against melanoma. The induction of immune activity against cancers such as melanoma is a promising approach to cancer treatment, but to date, only a few…
- Trial name
- NCT01216436
- Testing
- Vaccination with RNA-transfected mature autologous DC
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Duke University
Epithelial High Grade Serous Ovarian Cancer
Elements of Adaptive Immunity in Epithelial Ovarian Cancer
The study seeks to evaluate the presence and correlation with clinical outcome of several components of adaptive immunity (TILs, TLS, plasma cells and PD-L1 expression) in tumor specimens of patients with EOC treated with…
- Trial name
- NCT07528911
- Testing
- Assessment of elements of adaptive immunity in tumor biopsies
- Where
- Greece
- Volunteers
- 687 people
- Sponsor
- Hellenic Cooperative Oncology Group
Pancreatic Cancer
Immune Response After Pancreatic Cancer Treatment
The aim of this project is to describe the differential immunologic responses of patients who undergo in situ IRE, margin accentuation IRE with surgical resection of the primary tumor, and surgical resection of the primary tumor…
- Trial name
- IRE Immuno (NCT03069599)
- Testing
- irreversible electroporation (IRE)
- Where
- Switzerland
- Volunteers
- 38 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Head and Neck Cancer
The Physiological Response to Routine Head and Neck Cancer Surgery
The main objective of this pilot study is to observe and document the range of changes in the blood concentrations of certain hormones, inflammatory chemicals and immune chemicals in response to the stimulus of Head and Neck…
- Trial name
- NCT01032096
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Immunogenicity, Hematological Malignancies
Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies
Covid-19 is associated with a mortality rate of 33-37% in patients with hematological malignancies. At present, the anti-SARS-CoV-2 vaccination represents the most effective strategy for the prevention of Covid-19.
- Conditions
- Immunogenicity, Hematological Malignancies, Covid-19, Vaccine Response Impaired
- Trial name
- NCT04878822
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Ospedale di Circolo - Fondazione Macchi
Cervical Cancer, Psychosocial Effects of Cancer and Its Treatment
Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer
RATIONALE: Telephone counseling after treatment may reduce stress and improve the well-being and quality of life of patients who have cervical cancer.
- Trial name
- NCT00086242
- Testing
- Psychosocial Telephone Counseling (PTC)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, Irvine
ALL, AML
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
Cure of leukemia after hematopoietic stem cell transplantation (HSCT) is sustained by the anti-leukemic effect of the grafted cells (graft-versus-leukemia (GVL)).
- Conditions
- ALL, AML, Acute GVHD, Tumor Immunity
- Trial name
- NCT02631993
- Testing
- Photochemotherapy
- Where
- Sweden
- Volunteers
- 47 people
- Sponsor
- Karolinska University Hospital
Metastatic Pancreatic Cancer
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for…
- Trial name
- NCT01417000
- Testing
- GVAX Pancreas, CRS-207, Cyclophosphamide
- Where
- 10 sites in United States
- Volunteers
- 93 people
- Sponsor
- Aduro Biotech, Inc.
Melanoma
Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune Response
The goal of this study is to find out about the safety of injecting the gene (DNA) for mouse TYRP2 in patients with melanoma. DNA is a material that contains the information needed to produce many substances in the body.
- Trial name
- NCT00680589
- Testing
- injection of mouse TYRP2 DNA
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission.
- Trial name
- NCT01347996
- Testing
- histamine dihydrochloride and IL-2
- Where
- Sweden
- Volunteers
- 84 people
- Sponsor
- Cytovia, Inc.
Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.
This is a single-center pharmacokinetic study evaluating the impact of residual pembrolizumab levels on the efficacy of salvage chemotherapy following immunotherapy in patients with non-small cell lung cancer (NSCLC) or recurrent…
- Trial name
- CPI (NCT07633613)
- Testing
- Blood sampling, Tumor biopsies for biobank establishment (optional)
- Volunteers
- 110 people
- Sponsor
- Centre Antoine Lacassagne
Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase II trial studies the effect of lenalidomide and vaccine in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Conditions
- Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene
- Trial name
- NCT01351896
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Anal Canal Cancer, Human Papillomavirus
Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal
Complete response is a rare event in metastatic anal cancer in the case of unresectable recurrence after radiochemotherapy. In the University Hospital Center of Besançon, 8 patients with metastatic anal cancer were treated…
- Trial name
- Epitopes-HPV01 (NCT01845779)
- Testing
- DCF regimen
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Multiple Myeloma
Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro
The purpose of this study is to better understand what effects Bortezomib, a drug used for multiple myeloma therapy, has on the immune system.
- Trial name
- NCT01472627
- Testing
- Blood draws
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Metastatic Breast Cancer
Phase II Study for Solid Metastatic Tumors
1. To induce immunity-mediated tumor response outside the radiation field (abscopal effect) after chemo-radiation of a metastatic site in metastatic breast cancer patients. 2. To monitor the induction of a T cell response. 3.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Solid Tumor
- Trial name
- NCT02474186
- Testing
- Radiation therapy, Xeloda, paclitaxel
- Volunteers
- 41 people
- Sponsor
- NYU Langone Health
Breast Cancer
Healing Touch, Quality of Life, and Immunity During Breast Cancer Treatment
The purpose of this research study is to understand effects of a complementary medicine therapy, Healing Touch on quality of life and immunity of patients who are receiving treatment for breast cancer.
- Trial name
- NCT00565305
- Testing
- Healing Touch, Standard Treatment
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Iowa